|
Delayed
Hong Kong S.E.
21:20:23 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 8.630 HKD | -0.80% |
|
-4.80% | +2.37% |
| 10-19 | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 10-19 | Major drugmakers turn to China for licensing deals | RE |
Company Valuation: CSPC Pharmaceutical Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 100,932 | 97,707 | 86,022 | 55,169 | 96,380 | 101,374 | - | - |
| Change | - | -3.19% | -11.96% | -35.87% | 74.7% | 5.18% | - | - |
| Enterprise Value (EV) 1 | 89,633 | 86,241 | 72,284 | 46,931 | 86,710 | 90,153 | 87,083 | 83,940 |
| Change | - | -3.79% | -16.18% | -35.07% | 84.76% | 3.97% | -3.41% | -3.61% |
| P/E | 14.7x | 14.1x | 13.5x | 12.1x | 21.8x | 9.99x | 14.7x | 13.8x |
| PBR | 3.17x | 2.86x | 2.39x | 1.62x | 2.56x | 2.26x | 2.11x | 1.96x |
| PEG | - | 14.13x | -1.73x | -0.5x | -9.88x | 0x | -0.5x | 2.08x |
| Capitalization / Revenue | 2.94x | 2.77x | 2.52x | 1.78x | 3.26x | 2.63x | 2.84x | 2.68x |
| EV / Revenue | 2.61x | 2.44x | 2.12x | 1.51x | 2.94x | 2.34x | 2.44x | 2.22x |
| EV / EBITDA | 9.5x | 9.43x | 8.39x | 6.22x | 12.1x | 6.57x | 9.09x | 7.86x |
| EV / EBIT | 10.7x | 10.8x | 9.77x | 7.68x | 15.6x | 7.4x | 10.8x | 9.91x |
| EV / FCF | 23.7x | 14.1x | 26.2x | 17.5x | 19.5x | 11.8x | 13.1x | 12.2x |
| FCF Yield | 4.22% | 7.11% | 3.82% | 5.71% | 5.12% | 8.47% | 7.63% | 8.23% |
| Dividend per Share 2 | 0.18 | 0.21 | 0.28 | 0.26 | 0.29 | 0.4601 | 0.3685 | 0.3917 |
| Rate of return | 2.13% | 2.56% | 3.86% | 5.44% | 3.44% | 5.18% | 4.15% | 4.41% |
| EPS 2 | 0.5773 | 0.5831 | 0.5376 | 0.3946 | 0.3859 | 0.8886 | 0.6025 | 0.6425 |
| Distribution rate | 31.2% | 36% | 52.1% | 65.9% | 75.2% | 51.8% | 61.2% | 61% |
| Net sales 1 | 34,309 | 35,292 | 34,175 | 31,046 | 29,533 | 38,487 | 35,696 | 37,829 |
| EBITDA 1 | 9,431 | 9,148 | 8,615 | 7,547 | 7,168 | 13,729 | 9,585 | 10,681 |
| EBIT 1 | 8,366 | 7,952 | 7,400 | 6,113 | 5,564 | 12,184 | 8,044 | 8,472 |
| Net income 1 | 6,901 | 6,949 | 6,382 | 4,632 | 4,409 | 10,145 | 7,019 | 7,511 |
| Net Debt 1 | -11,298 | -11,467 | -13,738 | -8,238 | -9,670 | -11,221 | -14,292 | -17,435 |
| Reference price 2 | 8.470 | 8.200 | 7.260 | 4.780 | 8.430 | 8.880 | 8.880 | 8.880 |
| Nbr of stocks (in thousands) | 11,916,370 | 11,915,520 | 11,848,756 | 11,541,665 | 11,433,025 | 11,416,025 | - | - |
| Announcement Date | 3/22/22 | 3/22/23 | 3/20/24 | 3/28/25 | 3/25/26 | - | - | - |
1HKD in Million2HKD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 9.99x | 2.34x | 6.57x | 5.18% | 12.92B | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 27.15x | 6.49x | 17.21x | 2.46% | 395.38B | |
| Weighted average by Cap. | 34.64x | 8.18x | 19.99x | 1.85% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 1093 Stock
- Valuation CSPC Pharmaceutical Group Limited
Select your edition
All financial news and data tailored to specific country editions
